Merck to Buy Acceleron Pharma for $11.5 Billion
September 30 2021 - 7:34AM
Dow Jones News
By Dave Sebastian
Merck & Co. has agreed to buy Acceleron Pharma Inc. for
$11.5 billion, bolstering the pharmaceutical giant's rare-disease
business.
The deal values Acceleron at $180 a share in cash, the companies
said Thursday. The Wall Street Journal on Monday reported that the
companies were nearing a deal.
The deal is one of Merck's biggest and represents a bet on
treatments for respiratory and blood diseases that Acceleron
specializes in. Acceleron's crown jewel is an experimental drug for
pulmonary arterial hypertension, a disease caused by high pressure
in the blood vessels leading from the heart to the lungs.
The companies expect the deal to close in the fourth
quarter.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
September 30, 2021 07:19 ET (11:19 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Nov 2024 to Nov 2024
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Nov 2023 to Nov 2024
